Attached files

file filename
10-K - 10-K - Sio Gene Therapies Inc.axovant3311810k.htm
EX-32.1 - EXHIBIT 32.1 - Sio Gene Therapies Inc.axovantexhibit321.htm
EX-31.2 - EXHIBIT 31.2 - Sio Gene Therapies Inc.axovantexhibit312.htm
EX-31.1 - EXHIBIT 31.1 - Sio Gene Therapies Inc.axovantexhibit311.htm
EX-23.2 - EXHIBIT 23.2 - Sio Gene Therapies Inc.axovantexhibit232.htm
EX-23.1 - EXHIBIT 23.1 - Sio Gene Therapies Inc.axovantexhibit231.htm
EX-21.1 - EXHIBIT 21.1 - Sio Gene Therapies Inc.axovantexhibit211.htm
EX-10.24 - EXHIBIT 10.24 - Sio Gene Therapies Inc.axovantexhib1024.htm
EX-10.23 - EXHIBIT 10.23 - Sio Gene Therapies Inc.axovantexhib1023.htm
EX-10.22 - EXHIBIT 10.22 - Sio Gene Therapies Inc.axovantexhib1022.htm
EX-10.21 - EXHIBIT 10.21 - Sio Gene Therapies Inc.axovantexhib1021.htm


Exhibit 32.2
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report on Form 10-K of Axovant Sciences Ltd. (the “Company”) for the period ended March 31, 2018 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Gregory Weinhoff, Principal Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that to his knowledge:
(1)the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: June 11, 2018
By:
/s/ Gregory Weinhoff
 
 
Gregory Weinhoff
 
 
Principal Financial Officer

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the SEC or its staff upon request.